Thermo Fisher Scientific Showcases Breadth of Clinical Chemistry Solutions at AACC 2009
CHICAGO--(BUSINESS WIRE)--Jul 21, 2009 - Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is showcasing its breadth of innovative technologies for clinical chemistry laboratories at the American Association for Clinical Chemistry's (AACC's) 2009 Annual Meeting. Exhibiting under the banner, “A Community of Clinical Laboratory Excellence,” the company will highlight its ability to offer complete workflow solutions, including assay kits, reagents and other consumables, laboratory equipment and analytical instrumentation. The Thermo Scientific clinical chemistry lineup will be featured in booth 2815 at AACC 2009, being held in Chicago from July 21 – 23.
“As a market leader in specialty diagnostics, we have a unique offering of Thermo Scientific solutions for all stages of the clinical chemistry workflow,” said Dr. Ian D. Jardine, vice president of global R&D for Thermo Fisher Scientific. “AACC is the leading event for customers working in clinical chemistry, clinical laboratory science and laboratory medicine disciplines, and provides us with an excellent opportunity to meet with existing and potential customers from around the world to demonstrate our breadth of solutions for their clinical research applications.”
The company's industry-leading Thermo Scientific portfolio of offerings in support of Clinical Laboratory Excellence will be on display at AACC in booth 2815. Among the technologies, products and capabilities featured are:
Immunoassays, Reagents and Consumables
Thermo Scientific CEDIA Mycophenolic Acid (MPA) Immunoassay – This new, in vitro diagnostic test enhances the Thermo Scientific line of immunosuppressant drug (ISD) monitoring immunoassays. Developed for the quantitative measurement of mycophenolic acid in human plasma, it requires no extraction and offers 2-point calibration, with quick turnaround time for results. These reagents have been optimized for a variety of clinical chemistry analyzers to aid in the management of mycophenolic acid therapy in renal and cardiac transplant patients.
Thermo Scientific Sera-Mag SpeedBeads Streptavidin-Blocked Particles – These magnetic particles provide low Non-Specific Binding (NSB) to help researchers capture a clean sample when preparing their application. With highly active streptavidin covalently bound to the surface, the particles have a greater target isolation of proteins and utilize fewer beads in the process. In addition, the beads eliminate the need for protein-based blockers. Applications include automated immunoassays, immunoprecipitation (isolation of target proteins) and protein purification.
Thermo Fisher Scientific will showcase its industry-leading portfolio of high-performance Thermo Scientific mass spectrometry (MS) instrumentation for clinical research, from high-end to routine analysis. These systems, integrated with the company's gas chromatography (GC) and liquid chromatography (LC) technologies, cover a wide range of growing clinical research applications, including quantitative methodologies for analyzing vitamin D and immunosuppressants. These technologies are also widely used for forensic toxicology applications such as testing for opiates, THC, testosterone, benzodiazepines, peptides and other endogenous compounds. Specific examples highlighted at AACC 2009 include:
Thermo Scientific Clinical Research and Forensic Toxicology Screening Solution – This new drug screening and confirmation solution for forensic toxicology is based on the Thermo Scientific Exactive benchtop LC/MS platform. It incorporates the ultrahigh resolution LC/MS capabilities of the company's proprietary Orbitrap™ technology and includes the Thermo Scientific Transcend TLX UHPLC-based multiplexing system with patented TurboFlow™ technology for online sample extraction.
Thermo Scientific GC/MS Solution for Forensic Toxicology – This forensic toxicology application demonstrates the advanced analytical capabilities of the Thermo Scientific TSQ Quantum GC triple stage quadrupole mass spectrometer for monitoring marijuana in oral fluid. Oral fluid analysis is becoming an increasingly popular alternative to blood and urine testing for the detection of illegal drugs. The powerful TSQ Quantum GC is capable of performing rapid and reliable confirmation and quantitation analyses and achieves excellent quantitative precision and linearity.
Thermo Scientific General Purpose Centrifuges – Making its debut at AACC is the Thermo Scientific Sorvall ST 16 one-liter general purpose centrifuge series for increased productivity and throughput. Combining a maximum capacity of 4x400 ml with a compact design, these centrifuges are ideal for everyday sample processing, including clinical protocols, cell culture applications, microplate processing and a variety of separation needs. Features include multilingual user interfaces and control technology to maximize run performance and reproducibility. In addition, integrated Thermo Scientific Fiberlite rotors are lightweight and robust to deliver higher G-force and faster speeds in a corrosion-free design.
Thermo Fisher Financial Services
Thermo Fisher Scientific will also highlight its financial services offering at AACC 2009 – a program that combines the purchase of reagents and consumables, equipment, instrumentation and services into one affordable monthly payment. The Financial Services program offers convenient financing options for customers, and helps to reduce their capital expenditures by consolidating charges for industry-leading products, service contracts and supplies. To learn about Thermo Fisher's full range of financial services, please visit www.thermo.com.
OEM Lecture Series and Technical Workshops
Thermo Fisher Scientific will host several educational workshops at AACC 2009, with staff members conducting lectures and technical workshops on a range of topics of interest to clinical chemists. For more information about the company's OEM lecture series and technical workshops at AACC, please visit www.thermo.com/aacc.
Thermo Fisher Scientific will host two technical workshops on Tuesday, July 21 and Wednesday, July 22. Topics to be featured include:
Thermo Fisher Scientific will also host two OEM lectures on Wednesday, July 22. Topics to be featured are:
For a full list of all press releases announcing product highlights at AACC 2009, please visit the online media room at www.thermofisher.com/aacc09.
Thermo Scientific is part of Thermo Fisher Scientific, the world leader in serving science.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With 2008 revenues of $10.5 billion, we employ approximately 34,000 people and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit www.thermofisher.com.
The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the Company's Quarterly Report on Form 10-Q for the period ended March 28, 2009, under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission and available in the “Investors” section of our Website under the heading “SEC Filings.” Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: competition and its effect on pricing, spending, third-party relationships and revenues; the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal growth; general worldwide economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; the effect of laws and regulations governing government contracts; the effect of competing with certain of our customers and suppliers; and the effect of rapid changes in the healthcare industry. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.
Contact: Thermo Fisher Scientific Inc.
Media Contact Information:
Karen Kirkwood, 781-622-1306
Investor Contact Information:
Ken Apicerno, 781-622-1111
Posted: July 2009